VALENCIA, Calif., Jan 27, 2005 /PRNewswire-FirstCall via COMTEX/ -- MannKind Corporation (Nasdaq: MNKD) will release 2004 fourth quarter financial results on Thursday, February 3, 2005 before the opening of the financial markets. Following the release, the company will host an investment community conference call beginning at 8:30 a.m. EST (5:30 a.m. PST). Management will provide a business update and discuss 2004 fourth quarter and full year financial results.

To participate in the live call by telephone, please dial (888) 463-4383 from the U.S., or (706) 679-5355 from outside the U.S. Those interested in listening to the conference call live via the internet may do so by visiting the Company's website at www.mannkindcorp.com.

A telephone replay of the call will be available for 48 hours by dialing (800) 642-1687 from the U.S., or (706) 645-9291 from outside the U.S., and entering reservation number 3368397. A replay will be available on MannKind's website for 14 days.

About MannKind Corporation

MannKind focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. The Company recently commenced Phase 3 clinical trials in Europe of its lead product, the Technosphere(R) Insulin System, to study its potential for the treatment of diabetes. This System consists of a proprietary dry powder Technosphere(R) formulation of insulin that is inhaled into the deep lung using the Company's MedTone(TM) inhaler. MannKind believes that the performance characteristics, unique kinetics, convenience and ease of use of its proprietary Technosphere(R) Insulin System may have the potential to change the way diabetes is treated. For more information on MannKind Corporation and its technology, visit www.mannkindcorp.com.

SOURCE MannKind Corporation

Dick Anderson, Chief Financial Officer of MannKind Corporation, +1-661-775-5302, danderson@mannkindcorp.com; or Investor Relations, Ina McGuinness, imcguinness@lhai.com, or Bruce Voss, both of Lippert